Drug Trial Radar · NCT06244992
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Jan 26, 2024
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Pyrotech Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD-1/L1 therapy in patients with locally advanced or metastatic solid tumors. The study is divided into two parts: Phase 1 (Part A) focuses on determining the pharmaceutically active dosage range and evaluating the safety profile of PTT-936 when administered as a monotherapy. Phase 2a (Part B) will assess the safety and efficacy of PTT-936 combined with anti-PD-1/L1 therapy in patients suitable for anti- PD-1/L1 monotherapy. The study aims to understand how PTT-936, alone or in combination, impacts tumor progression and patients' overall response.
Conditions
- Locally Advanced or Metastatic Solid Tumors
Interventions
PTT-936Drug
Eligible patients will receive single-agent PTT-936 administered per orally (PO).
Combination of PTT-936 and anti-PD-1/L1 therapyDrug
Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TEAEs and TRAEs (with severity determined using NCI CTCAE v5.0), Grade >3 TEAEs, Grade >3 TRAEs, SAEs, and AESIsTime frame: 7 months
- Overall Response Rate (ORR): defined as the percentage of patients who achieved Complete Response (CR) or Partial Response (PR) according to RECIST v1.1 and iRECIST during the studyTime frame: 7 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Precision NextGen Oncology and Research Center
Beverly Hills, California · Recruiting
D&H Cancer Research Center
Margate, Florida · Recruiting
The START Center
San Antonio, Texas · Recruiting
Beijing Cancer Hospital
Beijing, China · Recruiting
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.